Zyprexa Payors Ask High Court For Shot At Eli Lilly

Law360, New York (April 13, 2011, 7:33 PM EDT) -- A group of third-party payors last month asked the U.S. Supreme Court to allow them to sue Eli Lilly & Co. over increased drug costs related to the company's alleged off-label and fraudulent marketing of its antipsychotic Zyprexa.

It does not make sense that government agencies and insurers should be able to recover $1.415 billion in fines, penalties and compensation over the marketing of Eli Lilly's Zyprexa while private insurers take nothing, a group of class action plaintiffs said in a petition filed Mar. 25 in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.